Business Context and Reporting Period
Company: Exponent, Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year End: January 3, 2003 (53-week year)
Business Overview: Exponent is a science and engineering consulting firm providing solutions to complex problems across 14 practice areas, including biomechanics, civil engineering, and environmental science. The company serves clients in automotive, aviation, government, and insurance sectors, often supporting litigation and failure prevention.
Key Financial Metrics (Fiscal Year 2002)
| Metric | 2002 | 2001 | 2000 |
|---|---|---|---|
| Revenues | $126.1 million | $114.5 million | $113.0 million |
| Operating Income | $13.9 million | $9.6 million | $10.7 million |
| Net Income | $7.9 million | $6.1 million | $7.8 million |
| Diluted EPS | $1.05 | $0.85 | $1.10 |
| Cash and Equivalents | $22.5 million | $7.8 million | $6.4 million |
| Working Capital | $44.7 million | $31.7 million | $24.0 million |
| Long-term Liabilities | $1.9 million | $1.2 million | $0.9 million |
| Operating Cash Flow | $16.3 million | $5.1 million | $21.1 million |
Margins: Operating margin improved to 11.0% in 2002 from 8.4% in 2001. Net income margin was 6.3% in 2002.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 10.1% to $126.1 million, driven by growth in both the "Environmental and Health" segment ($6.3 million increase) and the "Other Scientific and Engineering" segment ($5.3 million increase). The 53-week fiscal year contributed approximately $1.2 million in revenue.
- Profitability: Operating income rose 44.7% to $13.9 million, and net income increased 29.4% to $7.9 million. This was aided by a 13.6% reduction in General and Administrative expenses, primarily due to the cessation of goodwill amortization under SFAS No. 142.
- Liquidity: Cash and cash equivalents nearly tripled to $22.5 million, supported by strong operating cash flow of $16.3 million and improved accounts receivable collection (Days Sales Outstanding reduced from 118 to 102 days).
- Acquisition: The company acquired Novigen Sciences, Inc. in May 2002 for $2.1 million cash and stock, adding a Food & Chemicals practice and contributing $3.1 million to revenue growth.
Guidance, Outlook, and Risks
- Outlook: Management anticipates realizing approximately $1.0 million in revenue from a new Phase I Objective Force Warrior contract with the U.S. Army in the first half of fiscal 2003. The effective tax rate is projected to be 43.5% for fiscal 2003.
- Capital Resources: The company maintains a revolving reducing mortgage note with $26.0 million available (outstanding balance $0). Management believes existing cash and this credit facility are sufficient for long-term needs, though future acquisitions may require additional funding.
- Risks:
- Customer Concentration: 19% of revenue comes from the transportation industry and 10% from government agencies. Loss of a major client in these sectors could materially impact results.
- Backlog: The company has no significant backlog; revenues are derived from client requests and are terminable at any time.
- Competition: Low barriers to entry and high competition in technical disciplines could lead to price reductions.
- Key Personnel: Success depends on attracting and retaining highly qualified technical staff.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 10% revenue growth, noting the one-time impact of the 53-week fiscal year and the Novigen acquisition.
- Client Concentration: Assess the risk associated with the top transportation and government clients, which collectively represent nearly 30% of gross revenues.
- Goodwill Accounting: Confirm the impact of SFAS No. 142 adoption, which eliminated goodwill amortization and boosted operating income by approximately $843,000 in 2002.
- Cash Flow Efficiency: Monitor the Days Sales Outstanding (DSO) metric, which improved significantly to 102 days, to ensure continued collection efficiency.
- Stock-Based Compensation: Review pro forma net income ($6.1 million) if stock-based compensation were calculated using the fair value method (SFAS No. 123), which is significantly lower than the reported $7.9 million.